Business

Syndax Announces Participation at Three Upcoming Investor Conferences

WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. ("Syndax," the "Company" or "we") (Nasdaq: SNDX), a clinical stage

articleSyndax Pharmaceuticals, Inc.September 2, 20214/company/syndax-pharmaceuticals-inc/news/syndax-announces-participation-at-three-upcoming-investor-conferences-2021-09-02
Syndax Announces Participation at Three Upcoming Investor Conferences

About this update from Syndax Pharmaceuticals, Inc.

[{"type":"text","content":"WALTHAM, Mass., Sept. 2, 2021 /PRNewswire/ -- Syndax Pharmaceuticals, Inc. (\"Syndax,\" the \"Company\" or \"we\") (Nasdaq: SNDX), a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that members of its management team will participate in three upcoming virtual investor conferences:\nA fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference at 9:30 a.m. ET on Thursday, September 9, 2021. A panel at the Citi 16th Annual BioPharma Virtual Conference at 9:45 a.m. ET on Friday, September 10, 2021. A fireside chat at the Baird Global Healthcare Conference at 8:30 a.m. ET on Tuesday, September 14, 2021. A live webcast of the Morgan Stanley presentation and Citi panel can be accessed from the Investor section of the Company's website at www.syndax.com, where a replay of the events will also be available for a limited time.\nAbout Syndax Pharmaceuticals, Inc. \nSyndax Pharmaceuticals is a clinical stage biopharmaceutical company developing an innovative pipeline of cancer therapies. The Company's pipeline includes SNDX-5613, a highly selective inhibitor of the Menin–MLL binding interaction, axatilimab, a monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor, and entinostat, a class I HDAC inhibitor. For more information, please visit www.syndax.com or follow the Company on Twitter and LinkedIn. \nSyndax Contacts\nInvestor ContactMelissa ForstArgot [email protected] Tel 212.600.1902\nMedia ContactTed [email protected] 212.798.9842\nSNDX-G\n \n View original content:https://www.prnewswire.com/news-releases/syndax-announces-participation-at-three-upcoming-investor-conferences-301368070.html\nSOURCE Syndax Pharmaceuticals, Inc.","length":3730,"tagName":"div"}]

More updates from Syndax Pharmaceuticals, Inc.